Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025

LISATA THERAPEUTICS, INC.

2025-Q1 EPS reported -$0.55 vs consensus -$0.54 ▼ miss (-1.7%)

Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.
Cash, equivalents, and marketable securities $25.8M as of Mar 31, 2025; runway into Q3 2026.
Cohort B of ASCEND trial (mPDAC) accepted for oral presentation at ESMO-GI July 2025; final analysis pending.
BOLSTER trial in first-line cholangiocarcinoma fully enrolled; topline data anticipated mid-2025.
Qilu's Phase 2 certepetide trial in China complete; Phase 3 start triggers $10M milestone payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.